Tilray Brands Extends Global Reach With Key Approvals and Launches

10.11.25 13:50 Uhr

Werte in diesem Artikel

Tilray Medical, a division of Tilray Brands TLRY, continues to expand its global medical cannabis footprint with key international developments. Through its joint venture with Top Tech Global Inc., the company has established Solana Life Group in Panama, which has received a medical cannabis license from the National Directorate of Pharmacy and Drugs to cultivate, manufacture, and distribute medical cannabis locally. Through this partnership, Tilray Medical aims to launch and expand the availability of medical cannabis products across Panama, improving access for patients in need.TLRY also broadened its European presence by expanding its Tilray Craft portfolio in Germany. The company launched five new cannabis flower products produced in Germany at Tilray’s EU GMP certified facility in Neumünster. Tilray Brands solidifies its global leader position in medical cannabis through continuous introduction of new genetics bred to pharmaceutical standards at Neumünster. Also, the company’s wholly owned subsidiary, FL Group S.R.L, entered a strategic partnership with Italy’s L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. (Molteni), to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. In Australia, Tilray Brand introduced its first medical cannabis edible, Good Supply Pastilles, a sugar-free, vegan-friendly option, underscoring its commitment to innovation and patient-focused treatment solutions worldwide.Peer UpdateAs of June 2025, Village Farms International VFF retained its position as one of Canada’s top three cannabis players, even while streamlining its retail portfolio. During the second quarter, the company noted strong performance in international medical export sales that jumped 690% year over year and 116% sequentially. VFF also began commercial shipments to the Netherlands in early 2025, contributing $2.4 million to incremental second-quarter revenues. It continues to distribute several leading cultivars in Germany through third-party partners. Looking ahead, VFF expects momentum in its international medical cannabis sales to remain strong through the remainder of 2025, driven by expanding market access across Europe. It continues to distribute several leading cultivars in Germany through third-party partners. Curaleaf Holdings, Inc. CURLF continues focusing on expanding its international business. The company recently got a license to operate in Turkey, a country with a nascent medical cannabis market. Curaleaf International, part of Curaleaf Holdings, launched Curaleaf-branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest-growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity, and patient care. The company also achieved EU-MDR certification for the world's first medically certified liquid cannabis inhalation device with plans to launch in the United Kingdom and other key European and Australian markets as regulations evolve.TLRY’s Price PerformanceIn the past three months, Tilray Brands’ shares have gained 34.8%, outperforming the industry’s 3.2% decline. The S&P 500 composite has grown 7.1% in the same period.Image Source: Zacks Investment ResearchDiscounted ValuationTLRY currently trades at a forward 12-month Price-to-Sales (P/S) of 2.94X compared with the industry average of 3.16X.Image Source: Zacks Investment ResearchTLRY Stock Estimate TrendIn the past 30 days, its loss per share estimate for 2025 has improved 6 cents. Image Source: Zacks Investment ResearchTLRY stock currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tilray Brands, Inc. (TLRY): Free Stock Analysis Report Village Farms International, Inc. (VFF): Free Stock Analysis Report Curaleaf Holdings, Inc. (CURLF): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Tilray (ex Aphria) und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Tilray (ex Aphria)

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Tilray (ex Aphria)

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Tilray (ex Aphria)

Wer­bung

Analysen zu Tilray (ex Aphria)

DatumRatingAnalyst
14.08.2019Tilray BuyThe Benchmark Company
05.06.2019Tilray PerformOppenheimer & Co. Inc.
15.05.2019Tilray Market PerformBMO Capital Markets
21.02.2019Aphria BuySeaport Global Securities
21.02.2019Tilray NeutralSeaport Global Securities
DatumRatingAnalyst
14.08.2019Tilray BuyThe Benchmark Company
15.05.2019Tilray Market PerformBMO Capital Markets
21.02.2019Aphria BuySeaport Global Securities
16.10.2018Tilray BuyThe Benchmark Company
DatumRatingAnalyst
05.06.2019Tilray PerformOppenheimer & Co. Inc.
21.02.2019Tilray NeutralSeaport Global Securities
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Tilray (ex Aphria) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen